International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

The Lancet

Volumn 391, Issue 10135, 2018, Pages 2128-2139

  Pagès, Franck ^a,b,c,d   Mlecnik, Bernhard ^a,b,c,e   Marliot, Florence ^a,b,c,d   Bindea, Gabriela ^a,b,c   Ou, Fang Shu ^f   Bifulco, Carlo ^g   Lugli, Alessandro ^h   Zlobec, Inti ^h   Rau, Tilman T ^h   Berger, Martin D ⁱ   Nagtegaal, Iris D ^j   Vink Börger, Elisa ^j   Hartmann, Arndt ^k   Geppert, Carol ^k   Kolwelter, Julie ^k   Merkel, Susanne ^k   Grützmann, Robert ^k   Van den Eynde, Marc ^l,m   Jouret Mourin, Anne ^l,m   Kartheuser, Alex ^l   Léonard, Daniel ^l   Remue, Christophe ^l   Wang, Julia Y ^n,o,p   Bavi, Prashant ^p   Roehrl, Michael H A ^o,p,q   Ohashi, Pamela S ^o   Nguyen, Linh T ^o   Han, SeongJun ^o   MacGregor, Heather L ^o   Hafezi Bakhtiari, Sara ^o   Wouters, Bradly G ^o   Masucci, Giuseppe V ^r   Andersson, Emilia K ^r   Zavadova, Eva ^s   Vocka, Michal ^s   Spacek, Jan ^s   Petruzelka, Lubos ^s   Konopasek, Bohuslav ^s   Dundr, Pavel ^s,t   Skalova, Helena ^s,t   Nemejcova, Kristyna ^s,t   Botti, Gerardo ^u   Tatangelo, Fabiana ^u   Delrio, Paolo ^u   Ciliberto, Gennaro ^v   Maio, Michele ^w   Laghi, Luigi ^x   Grizzi, Fabio ^x,y   Fredriksen, Tessa ^a,b,c   Buttard, Bénédicte ^a,b,c   Angelova, Mihaela ^a,b,c   Vasaturo, Angela ^a,b,c   Maby, Pauline ^a,b,c   Church, Sarah E ^a,b,c,z   Angell, Helen K ^a,b,c,aa   Lafontaine, Lucie ^a,b,c   Bruni, Daniela ^a,b,c   El Sissy, Carine ^a,b,c,d   Haicheur, Nacilla ^d   Kirilovsky, Amos ^a,b,c,d   Berger, Anne ^a,b,c,d   Lagorce, Christine ^a,b,c,d   Meyers, Jeffrey P ^f   Paustian, Christopher ^g   Feng, Zipei ^g   Ballesteros Merino, Carmen ^g   Dijkstra, Jeroen ^j   van de Water, Carlijn ^j   van Lent van Vliet, Shannon ^j   Knijn, Nikki ^j   Mușină, Ana Maria ^ab   Scripcariu, Dragos Viorel ^ab   Popivanova, Boryana ^ac   Xu, Mingli ^ac   Fujita, Tomonobu ^ac   Hazama, Shoichi ^ad   Suzuki, Nobuaki ^ae   Nagano, Hiroaki ^ae   Okuno, Kiyotaka ^af   Torigoe, Toshihiko ^ag   Sato, Noriyuki ^ag   Furuhata, Tomohisa ^ag   Takemasa, Ichiro ^ag   Itoh, Kyogo ^ah   Patel, Prabhu S ^ai   Vora, Hemangini H ^ai   Shah, Birva ^ai   Patel, Jayendrakumar B ^ai   Rajvik, Kruti N ^ai   Pandya, Shashank J ^ai   Shukla, Shilin N ^ai   Wang, Yili ^aj   Zhang, Guanjun ^aj   Kawakami, Yutaka ^ac   Marincola, Francesco M ^ak   Ascierto, Paolo A ^u   Sargent, Daniel J ^f   Fox, Bernard A ^g,al   Galon, Jérôme ^a,b,c   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e Inovarion   (France)

^f MAYO CLINIC   (United States)

^g PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

ⁿ Curandis Laboratories   (United States)

^o UNIVERSITY HEALTH NETWORK   (Canada)

^p UNIVERSITY OF TORONTO   (Canada)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r KAROLINSKA INSTITUTE   (Sweden)

^s CHARLES UNIVERSITY   (Czech Republic)

^t CHARLES UNIVERSITY   (Czech Republic)

^u NATIONAL CANCER INSTITUTE   (Italy)

^v REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^w UNIVERSITY HOSPITAL OF SIENA   (Italy)

^x HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^y HUMANITAS UNIVERSITY   (Italy)

^z NANOSTRING TECHNOLOGIES   (United States)

^aa ASTRAZENECA   (United Kingdom)

^ab GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^ac KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ad YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ae YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^af KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ag SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ah KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ai GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

^aj MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^ak SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^al OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CLINICAL OUTCOME; COLON CARCINOMA; COMPARATIVE STUDY; CONSENSUS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSCORE ASSAY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; QUANTITATIVE ANALYSIS; RECURRENCE RISK; SEX; TUMOR ASSOCIATED LEUKOCYTE; VALIDATION STUDY; ADULT; CLASSIFICATION; COLON TUMOR; ETIOLOGY; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; TUMOR RECURRENCE;

ADULT; AGED; COLONIC NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS;

EID: 85046846915     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30789-X     Document Type: Article

References (33)

1. Locker, GY, Hamilton, S, Harris, J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24 (2006), 5313–5327.
2. Sobin, L, Wittekind, C, TNM classification of malignant tumors. 2002, Wiley-Liss, New York, NY.
3. Weitz, J, Koch, M, Debus, J, Hohler, T, Galle, PR, Buchler, MW, Colorectal cancer. Lancet 365 (2005), 153–165.
4. Galon, J, Mlecnik, B, Bindea, G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232 (2014), 199–209.
5. Guinney, J, Dienstmann, R, Wang, X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 21 (2015), 1350–1356.
6. Fridman, WH, Pages, F, Sautes-Fridman, C, Galon, J, The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12 (2012), 298–306.
7. Galon, J, Angell, HK, Bedognetti, D, Marincola, FM, The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26.
8. Galon, J, Costes, A, Sanchez-Cabo, F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
9. Koelzer, VH, Dawson, H, Andersson, E, et al. Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. Transl Res 166 (2015), 207–217.
10. Laghi, L, Bianchi, P, Miranda, E, et al. CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10 (2009), 877–884.
11. Lee, WS, Park, S, Lee, WY, Yun, SH, Chun, HK, Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 116 (2010), 5188–5199.
12. Mlecnik, B, Bindea, G, Angell, HK, et al. Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44 (2016), 698–711.
13. Mlecnik, B, Tosolini, M, Kirilovsky, A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29 (2011), 610–618.
14. Nosho, K, Baba, Y, Tanaka, N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer and prognosis: cohort study and literature review. J Pathol 222 (2010), 350–366.
15. Ogino, S, Galon, J, Fuchs, CS, Dranoff, G, Cancer immunology—analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8 (2011), 711–719.
16. Ogino, S, Nosho, K, Irahara, N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15 (2009), 6412–6420.
17. Pages, F, Berger, A, Camus, M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 (2005), 2654–2666.
18. Sinicrope, FA, Rego, RL, Ansell, SM, Knutson, KL, Foster, NR, Sargent, DJ, Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137 (2009), 1270–1279.
19. Emile, JF, Julie, C, Le Malicot, K, et al. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer 82 (2017), 16–24.
20. Pages, F, Kirilovsky, A, Mlecnik, B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27 (2009), 5944–5951.
21. Mlecnik, B, Bindea, G, Angell, HK, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med, 6, 2014, 228ra37.
22. Broussard, EK, Disis, ML, TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol 29 (2011), 601–603.
23. Bindea, G, Mlecnik, B, Tosolini, M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
24. Berghoff, AS, Fuchs, E, Ricken, G, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology, 5, 2016, e1.
25. Mlecnik, B, Van den Eynde, M, Bindea, G, et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst 110 (2018), 97–108.
26. Concha-Benavente, F, Ferris, RL, Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 45 (2017), 52–59.
27. Whiteside, TL, Demaria, S, Rodriguez-Ruiz, ME, Zarour, HM, Melero, I, Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res 22 (2016), 1845–1855.
28. Galon, J, Pages, F, Marincola, FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med, 10, 2012, 1.
29. Grothey, A, Sobrero, AF, Shields, AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378 (2018), 1177–1188.
30. MacCarty, W, Mahle, A, Relation of differentiation and lymphocytic infiltration to postoperative longevity in gastric carcinoma. J Lab Clin Med, 6, 1921, 473.
31. Mlecnik, B, Bindea, G, Kirilovsky, A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med, 8, 2016, 327ra26.
32. Benson, AB 3rd, Hamilton, SR, Path toward prognostication and prediction: an evolving matrix. J Clin Oncol 29 (2011), 4599–4601.
33. Emens, LA, It's TIME for a biomarker-driven approach to cancer immunotherapy. J Immunother Cancer, 4, 2016, 43.